Consistent with our results, GSKJ-4 treatment did decrease the expression of JMJD3 in fibroblast-like synoviocytes (Jia et al., 2018), breast cancer stem cells (Yan et al., 2017) and renal interstitial fibroblasts in vitro (Yu et al., 2021). This evidence concerns the gene KDM6B and breast carcinoma.